Taiwan and Singapore back NSV’s US$53M bet on Asia’s biotech pipeline

Raising a debut fund in 2026 is hard. Raising one for biotech, a sector investors have spent four years avoiding, is harder still. NeoSci Ventures (NSV) says it has done it anyway. The Singapore-, Taiwan- and US-based venture builder has announced a first close of SGD70 million (US$53 million) for…